Dr. Myla D. Goldman, MD

Dr. Goldman practices at VCU Medical Center in Richmond, Virginia, part of Commonwealth of Virginia.

Dr. Goldman's NPI, 1649208141, was assigned on June 30, 2006. Dr. Goldman graduated from Rush Medical College of Rush University in 1999. Dr. Goldman holds Virginia license 0101240571.

Dr. Goldman's primary practice is VCU Medical Center, at 1250 East Marshall Street, Richmond, VA 23298 in Richmond City. The practice phone is (804) 828-9000.

Dr. Goldman's primary practice is VCU Medical Center in Richmond, Virginia, part of Commonwealth of Virginia. The medical group on file is UVA Physicians Group. Dmand AI also links Dr. Goldman to 1 more group practice or clinic, 1 urgent care center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Goldman practices, 3 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Goldman's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Goldman is licensed in Virginia.

CMS data shows 127 Medicare services from Dr. Goldman across 3 procedure codes in 2024, for 69 Medicare patients. Medicare paid $7,339 for them. Every service was in an office.

CMS counts 69 Medicare patients who saw Dr. Goldman in 2024. The largest group is 65 to 74, with 28 patients. 58% of them have high cholesterol, and 48% have arthritis. Their average risk score is 1.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Goldman's median patient age at 60, with 74% women.

In 2024, Dr. Goldman wrote 883 Medicare Part D claims for 90 patients. 83% of them were for generic drugs. CMS names the drug for 724 of them, across 23 drugs with 11 or more claims each, at $1,249,828 in total drug cost. In 2023, CMS named 611 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Goldman for performance year 2024, reported as part of a group. Dr. Goldman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Goldman as offering telehealth.

Dmand AI links 69 papers to Dr. Goldman, published from 2010 to 2025. 2016 was the busiest year, with 9. The most frequent topics are Multiple Sclerosis, Walking and Disease Progression. Dr. Goldman has published most often in Neurol Neuroimmunol Neuroinflamm. Dr. Goldman's most frequent co-authors are James N. Brenton, MD, Diego Cadavid, MD and Claire Sebastian Riley, MD.

Dmand AI links Dr. Goldman to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting and Multiple Sclerosis, Chronic Progressive. Open Payments lists research payments to Dr. Goldman that name 1 trial.

CMS Open Payments shows 238 general payments to Dr. Goldman from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 71% of the total. Sanofi and Genzyme US Companies paid the most, $58,492. It also lists 3 research payments totaling $2,326 from 2018 to 2019, naming 1 clinical trial.

Dr. Goldman graduated from Rush Medical College of Rush University in 1999.